Abstract
Heroin addiction is a wide-reaching problem with a spectrum of damaging social consequences. Currently approved heroin addiction medications include drugs that bind at the same receptors (e.g. opioid receptors) occupied by heroin and/or its metabolites in the brain, but undesired side effects of these treatments, maintenance dependence and relapse to drug taking remains problematic. A vaccine capable of blocking heroin's effects could provide an economical, long-lasting and sustainable adjunct to heroin addiction therapy without the side effects associated with available treatment options. Heroin, however, presents a particularly challenging vaccine target as it is metabolized to multiple psychoactive molecules of differing lipophilicity, with differing abilities to cross the blood brain barrier. In this review, we discuss the opiate scaffolding and hapten design considerations to confer immunogenicity as well as the specificity of the immune response towards structurally similar opiates. In addition, we detail different strategies employed in the design of immunoconjugates for a vaccine-based therapy for heroin addiction treatment.
Keywords: Heroin, 6-acety-morphine, morphine, addiction, drug dependence, immunoconjugate, treatment, therapy, HIV, AChE, Blood Brain Barrier, Rehabilitation Therapy, Keyhole Limpet Hemocyanin, ELISA
CNS & Neurological Disorders - Drug Targets
Title: Developing a Vaccine Against Multiple Psychoactive Targets: A Case Study of Heroin
Volume: 10 Issue: 8
Author(s): G. Neil Stowe, Joel E. Schlosburg, Leandro F. Vendruscolo, Scott Edwards, Kaushik K. Misra, Gery Schulteis, Joseph S. Zakhari, George F. Koob and Kim D. Janda
Affiliation:
Keywords: Heroin, 6-acety-morphine, morphine, addiction, drug dependence, immunoconjugate, treatment, therapy, HIV, AChE, Blood Brain Barrier, Rehabilitation Therapy, Keyhole Limpet Hemocyanin, ELISA
Abstract: Heroin addiction is a wide-reaching problem with a spectrum of damaging social consequences. Currently approved heroin addiction medications include drugs that bind at the same receptors (e.g. opioid receptors) occupied by heroin and/or its metabolites in the brain, but undesired side effects of these treatments, maintenance dependence and relapse to drug taking remains problematic. A vaccine capable of blocking heroin's effects could provide an economical, long-lasting and sustainable adjunct to heroin addiction therapy without the side effects associated with available treatment options. Heroin, however, presents a particularly challenging vaccine target as it is metabolized to multiple psychoactive molecules of differing lipophilicity, with differing abilities to cross the blood brain barrier. In this review, we discuss the opiate scaffolding and hapten design considerations to confer immunogenicity as well as the specificity of the immune response towards structurally similar opiates. In addition, we detail different strategies employed in the design of immunoconjugates for a vaccine-based therapy for heroin addiction treatment.
Export Options
About this article
Cite this article as:
Neil Stowe G., E. Schlosburg Joel, F. Vendruscolo Leandro, Edwards Scott, K. Misra Kaushik, Schulteis Gery, S. Zakhari Joseph, F. Koob George and D. Janda Kim, Developing a Vaccine Against Multiple Psychoactive Targets: A Case Study of Heroin, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219316
DOI https://dx.doi.org/10.2174/187152711799219316 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Statins: Are They All the Same?
Current Drug Therapy Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Foreword
Current Pharmaceutical Design Therapeutic Aspects of Squill; An Evidence-Based Review
Current Drug Discovery Technologies New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Preface
Current Medicinal Chemistry <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s: Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists
Current Drug Targets - Infectious Disorders Molecular Docking, DFT Studies and ADMET Simulations for Evaluating Already Approved FDA Drugs as Inhibitors for SARS-Cov-2 RNADependent Polymerase
Letters in Drug Design & Discovery Hematological Targets of Radiation Damage
Current Drug Targets Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Beyond Physical Exercise: The Role of Nutrition, Gut Microbiota and Nutraceutical Supplementation in Reducing Age-Related Sarcopenia
Current Aging Science Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews